Luye Pharmaceutical's new drug LY03010 may improve treatment...
Luye Pharmaceutical's new drug LY03010 may improve treatment compliance and reduce recurrence in patients with schizophrenia. The company has a strategic layout and superior products in the field of CNS treatment, showing ambition to further develop this field. The superior R&D, clinical registration, supply chain and commercialization capabilities established globally prepare for the global commercialization of new products in the future.
![](https://pubimg-10000538.picsh.myqcloud.com/2022050900000158c08681873ad.jpg)
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment